Thursday, 19 July 2018 - 6:45
  • it
  • de
  • en
  • fr

Ultibro Breezhaler

Novartis announces results of CRYSTAL trial in COPD

Novartis announced positive results from CRYSTAL, a prospective, open-label, multicenter, 12-week trial. Patients were recruited into four groups and randomized to a direct switch to Seebri Breezhaler (glycopyrronium) 50 mcg or Ultibro Breezhaler (indacaterol/glycopyrronium) 110/50 mcg once daily vs. continuation…

Ultibro Breezhaler vs Seretide for COPD: new findings

Published findings from new analyses within the FLAME study confirmed that Novartis’ Ultibro Breezhaler is more effective than Seretide for several subpopulations of patients with COPD. Once-daily Ultibro Breezhaler 110/50 mcg demonstrated consistent reductions in the rate of exacerbation, regardless…